Imaging Alzheimer pathology in late-life depression with PET and Pittsburgh Compound-B

Alzheimer Disease and Associated Disorders

Volumn 22, Issue 3, 2008, Pages 261-268

  Butters, Meryl A ^a,e   Klunk, William E ^a   Mathis, Chester A ^a   Price, Julie C ^a,b   Ziolko, Scott K ^a   Hoge, Jessica A ^a   Tsopelas, Nicholas D ^a   Lopresti, Brian J ^a   Reynolds III, Charles F ^a   DeKosky, Steven T ^a   Meltzer, Carolyn C ^a,c,d  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d EMORY UNIVERSITY   (United States)

^e UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Alzheimer disease; Amyloid; Brain; Depression; Emission tomography

Indexed keywords

AMYLOID; PITTSBURGH COMPUND B C 11; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN CORTEX; BRAIN REGION; CLINICAL ARTICLE; COGNITION; COGNITIVE DEFECT; DATA ANALYSIS; DRUG RETENTION; FEMALE; HUMAN; MAJOR DEPRESSION; MALE; MENTAL CAPACITY; NEUROIMAGING; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

AGE OF ONSET; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANILINE COMPOUNDS; BRAIN; DEPRESSION; FEMALE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; THIAZOLES;

EID: 52649141742     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/WAD.0b013e31816c92bf     Document Type: Article

References (73)

1. Kral VA, Emery OB. Long-term follow-up of depressive pseudode-mentia of the aged. Can J Psychiatry. 1989;34:445-446.
2. Reynolds C, Kupfer D, Hoch C, et al. Two-year follow-up of elderly patients with mixed depression and dementia. Clinical and electro- encephalographic sleep findings. J Am Geriatr Soc. 1986;34:793-799.
3. Sachdev P, Smith J, Angus-Lepan H, et al. Pseudodementia twelve years on. J Neurol Neurosurg Psychiatry. 1990;53:254-259.
4. Jorm AF. History of depression as a risk factor for dementia: an updated review. Aust N Z J Psychiatry. 2001;35:776-781.
5. Ownby R, Crocco E, Acevedo A, et al. Depression and risk for Alzheimer disease. Systemic review, meta-analysis, and meta regression analysis. Arch Gen Psychiatry. 2006;53:530-538.
6. Green RC, Cupples LA, Kurz A, et al. Depression as a risk factor for Alzheimer disease: the MIRAGE Study. Arch Neurol. 2003;60: 753-759.
7. Fischer P, Simanyi M, Danielczyk W. Depression in dementia of the Alzheimer type and in multi-infarct dementia. Am J Psychiatry. 1990;147:1484-1487.
8. Komahashi T, Ohmori K, Nakano T, et al. Epidemiological survey of dementia and depression among the aged living in the community in Japan. Jpn J Psychiatry Neurol. 1994;48:517-526.
9. Lopez OL, Becker JT, Sweet RA, et al. Psychiatric symptoms vary with the severity of dementia in probable Alzheimer's disease. J Neuropsychiatry Clin Neurosci. 2003;15:346-353.
10. Payne J, Sheppard J, Steinberg M, et al. Incidence, prevalence, and outcomes of depression in residents of a long-term care facility with dementia. Int J Geriatr Psychiatry. 2002;17:247-253.
11. Alexopoulos G, Meyers B, Young R, et al. The course of geriatric depression with "reversible dementia": a controlled study. Am J Psychiatry. 1993;150:1693-1699.
12. Lyketsos CG, Lopez O, Jones B, et al. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA. 2002;288:1475-1483.
13. Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56:303-308.
14. Bowen J, Teri L, Kukull W, et al. Progression to dementia in patients with isolated memory loss. Lancet. 1997;349:763-765.
15. Devanand DP, Folz M, Gorlyn M, et al. Questionable dementia: clinical course and predictors of outcome. J Am Geriatr Soc. 1997; 45:321-328.
16. Yesavage JA, O'Hara R, Kraemer H, et al. Modeling the prevalence and incidence of Alzheimer's disease and mild cognitive impairment. J Psychiatr Res. 2002;36:281-286.
17. Petersen RC, Doody R, Kurz A, et al. Current concepts in mild cognitive impairment. Arch Neurol. 2001;58:1985-1992.
18. Lopez O, Jagust W, DeKosky S, et al. Prevalence and classification of mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 1. Arch Neurol. 2003;60:1385-1389.
19. Butters M, Whyte E, Nebes R, et al. Neuropsychological functioning and clinical correlates of late-life depression. Arch Gen Psychiatry. 2004;61:587-595.
20. Bhalla R, Butters M, Mulsant B, et al. Persistence of neuropsychological deficits in the remitted state of late-life depression. Am J Geriatr Psychiatry. 2006;14:419-427.
21. Hardy J, Higgins G. Alzheimer's disease: the amyloid cascade hypothesis. Science. 1992;256:184-185.
22. Hyman BT, West HL, Rebeck GW, et al. Quantitative analysis of senile plaques in Alzheimer disease: observation of log-normal size distribution and molecular epidemiology of differences associated with apolipoprotein E genotype and trisomy 21 (Down syndrome). Proc Nat Acad Sci U S A. 1995;92:3586-3590.
23. DeKosky ST, Ikonomovic MD, Styren SD, et al. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol. 2002;51:145-155.
24. Davis P, Mohs R, Marin D, et al. Cholinergic markers in elderly patients with early signs of Alzheimer disease. J Am Med Assoc. 1999;281:1401-1406.
25. Klunk W, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease using the novel PET tracer, PIB. Ann Neurol. 2004;55:306-319.
26. Shoghi-Jadid K, Small GW, Agdeppa ED, et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry. 2002;10:24-35.
27. Price J, Klunk W. Lopresti B. et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound- B. J Cereb Blood Flow Metab. 2005;125:1528-1547.
28. Lopresti B, Klunk W, Mathis C. et al. Simplified quantification of Pittsburgh Compound-B amyloid imaging PET studies: a compara tive analysis. J Nucl Med. 2005;6:1959-1972.
29. Ziolko S, Weissfeld L, Klunk W. et al. Evaluation of voxel-based methods for the statistical analysis of PIB PET amyloid imaging studies in Alzheimer's disease. Neuroimage. 2006;33: 94-102.
30. Forsberg A, Engler H. Almkvist O, et al. PET imaging of amyloid deposition in Ppatients with mild cognitive impairment. Neurobiol Aging. 2007; epub ahead of print.
31. Kemppainen NM, Aalto S, Wilson I A, et al. PET amyloid ligand [11C] PIB uptake is increased in mild cognitive impairment. Neurology. 2007;68:1603-1606.
32. Pike KE, Savage G, Villemagne VL, et al. beta-amyloid imaging and memory in non-demented individuals: evidence for pre-clinical Alzheimer's disease. Brain. 2007;130:2837-2844.
33. First M, Spitzer R, Gibbon M, et al. Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition (SC/D-I/P). New York: New York Psychiatric Institute; 1995.
34. Folstein MF, Folstein SE, McHugh PR. Mini-mental state: a practical method grading the cognitive state of patients for the clinician. Psychiatr Res. 1975;12:189-198.
35. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
36. Wechsler D. Wechsler Adult Intelligence Scale III. San Antonio: The Psychological Corporation; 1996.
37. Matthews CG, Klove H. Instruction Manual for the Adult Neuropsychology Test Battery. Madison, WI: University of Wisconsin Medical School; 1964.
38. Reitan RM, Wolfson D. The Halstead-Reitan Neuropsychologicai Test Battery. Tucson: Neuropsychology Press; 1993.
39. Goodglass H, Kaplan E, Weintraub S. The Assessment of Aphasia and Related Disorders. 2nd edn. Philadelphia: Lea & Febiger; 1983.
40. Rouleau I, Salmon DP, Butters N, et al. Quantitative and qualitative analyses of clock drawings in Alzheimer's and Huntington's disease. Brain Cogn. 1992;18:70-87.
41. Royall DR, Mahurin RK, Gray KF. Beside assessment of executive cognitive impairment: the executive interview. J Am Geriatr Soc. 1992;40:1221-1226.
42. Trenerry MR, Crosson B, De Boe J, et al. Stroop Neuropsychologicai Test. Odessa, FL: Psychological Assessment Resources; 1989.
43. Berg EA. A simple objective technique for measuring flexibility in thinking, using a sorting method. J Gen Psychol. 1948;39:15-22.
44. Borkowski JG, Benton AL, Spreen O. Word fluency and brain damage. Neuropsychologia. 1967;5:135-140.
45. Baddeley A, Emslie H, Smith IN. The Speed and Capacity of Language Processing (SCOLP) Test Manual. England: Bury St. Edmunds; 1992.
46. Wechsler D. Wechsler Memory Scale-Ill. San Antonio: The psychological corporation; 1996.
47. Osterreith PA. Le test de copie d'un figure complexe. Arch Psychologie. 1944;30:206-356.
48. Rey A. L'examinen psychologie dans les cas d'encephalopathie traumatique. Arch Psychologie. 1941;30:286-340.
49. Delis D, Kramer J, Kaplan E, et al. California Verbal Learning Test. New York: Psychological Corporation; 1987.
50. Mathis C, Wang Y, Holt D, et al. Synthesis and evaluation of 11C-labeled 6-substituted 2-aryI benzothiazoles as amyloid imaging agents. J Med Chem. 2003;46:2740-2755.
51. Weinhard K. Applications of 3D PET. In: Bendriem B, Townsend D. eds. The Theory and Practice of 3D PET. Boston: Kluwer Academic Publishers; 1998:133-167.
52. Watson C, Newport D, Casey M, et al. Evaluation of simulation- based scatter correction for 3D PET cardiac imaging. IEEE Trans Nucl Sci. 1997;44:90-97.
53. Woods RP, Mazziotta JC, Cherry SR. MRI-PET registration with automated algorithm. J Comput Assist Tomogr. 1993;17:536-546.
54. Smith S. Fast robust automated brain extraction. Hum Brain Mapp. 2002;17:143-155.
55. Logan J, Fowler JS, Volkow ND, et al. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)- cocaine PET studies in human subjects. J Cereb Blood Flow Metab. 1990;10:740-747.
56. Logan J. Graphical analysis of PET data applied to reversible and irreversible tracers. Nucl Med Biol. 2000;27:661-670.
57. Kwong K, Belliveau J, Chesler D, et al. Dynamic magnetic resonance imaging of human brain activity during primary sensory stimulation. Proc Natl Acad Sci U S A. 1992;89:5675-5679.
58. Meltzer CC, Leal JP. Mayberg HS, et al. Correction of PET data for partial volume effects in human cerebral cortex by MR imaging. J Comput Assist Tomogr. 1990;14:561-570.
59. Meltzer C, Drevets W, Price J, et al. Gender-specific aging reductions in [11C-carbonyl] WAY100635 binding: not an effect of atrophy. Neuroimage. 2000;11:S14.
60. SPSS Inc. SPSS Base 14.0 for Windows User's Guide. 2005, Chicago IL.
61. Thal DR, Rub U, Orantes M, et al. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58:1791-1800.
62. Mirra S, Heyman A, McKeel D, et al. The consortium to establish a registry for Alzheimer's disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991;41:479-486.
63. Petersen RC, Thomas R, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. New Engl J Med. 2005;352:2379-2388.
64. Hanninen T, Hallikainen M, Koivisto K, et al. A follow-up study of age-associated memory impairment: neuropsychological predictors of dementia. J Am Geriatr Soc. 1995;43:1007-1015.
65. Morris JC, Storandt M, Miller JP, et al. Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol. 2001;58: 397-405.
66. Gauthier S, Touchon J. Mild cognitive impairment is not a clinical entity and should not be treated. Arch Neurol. 2005;62:1164-1166.
67. Rapp M, Schnaider-Berri M, Grossman H, et al. Increased hippocampal plaques and tangles in patients with Alzheimer disease with a lifetime history of major depression. Arch Gen Psychiatry. 2006;63:161-167.
68. Sweet R, Hamilton R, Butters M, et al. Neuropathologic correlates of late-onset major depression. Neuropsychopharmacology. 2004;29: 2224-2225.
69. Krishnan K, Hays J, Blazer D. MRI-defined vascular depression. Am J Psychiatry. 1997;154:497-501.
70. Deuschle M, Weber B, Colla M, et al. Effects of major depression, aging and gender upon calculated diurnal free plasma cortisol concentrations: a re-evaluation study. Stress. 1998;2:281-287.
71. Meltzer C, Price J, Mathis C, et al. Serotonin 1A receptor binding and treatment response in late-life depression. Neuropsvchopharmacology. 2004;29:2258-2265.
72. Kumar A, Schweizer E, Jin Z, et al. Neuroanatomical substrates of late-life minor depression. A quantitative magnetic resonance imaging study. Arch Neurol. 1997;54:613-617.
73. Steffens DC, Hays J, Krishnan KR. Disability in geriatric depression. Am J Geriatr Psychiatry. 1999;7:34-40.